Leadiant Biosciences that the FDA has granted approval to Revcovi (elapegademase-lvlr) injection in the U.S. Revcovi is a new enzyme replacement therapy (ERT) for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients. “We are gratified by the FDA’s timely recognition of Revcovi as an effective and safe treatment for ADA-SCID,…
Leadiant Biosciences and The National Institutes of Health Collaborate on GNE Myopathy Therapy
Leadiant Biosciences, Inc. has entered into a license agreement and cooperative research and development agreement (CRADA) with the National Institutes of Health (NIH) to develop oral N-acetyl-D-mannosamine (ManNAc) for the potential treatment of individuals with GNE myopathy. GNE myopathy is a rare genetic disorder that causes progressive skeletal muscle atrophy, with an onset in young adulthood,…